思覺失調症 - 競爭情形:2020年

藥物開發企業主要的焦點，是5-hydroxytryptamine(5-HT)和多巴胺受體。在開發平台有143種藥物，其中39種以5-HT或多巴胺受體作為標的。在這個適應症，大型製藥企業支配著研究開發。預計發生率增加，促進思覺失調症治療藥市場成長。

本報告提供全球思覺失調症治療藥的現在、未來的競爭情形相關的系統性資訊。

目錄

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 上市藥的評估

• 上市藥概要
• 上市藥的簡介

第5章 開發平台的評估

• 開發平台概要
• 開發平台的明細:各地區
• 開發平台的明細:各分子類型，各標的
• 醫藥品審查的指定
• 相變的成功率
• 核準的可能性

第6章 臨床試驗的評估

• 臨床試驗概要:各階段
• 概要:各地區
• 治療領域預測
• 主要贊助商
• 登記分析
• 實行可能性分析

第7章 商業性評估

• 未來市場促進因素

第8章 社群媒體與數位行銷

• 主要的Twitter Chatter
• 領導品牌的網站
• 信任來源和引用來源

第9章 附錄

GlobalData's "Schizophrenia - Competitive Landscape in 2020" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

5-hydroxytryptamine (5-HT) and dopamine receptors are the major focus of drug developers. There are 143 drugs in the pipeline, 39 of which targets 5-HT or dopamine receptors. Big pharma dominates R&D in this indication, with Otsuka, Johnson & Johnson, Lundbeck, and Roche leading the way. Increasing incidence expected to drive growth in schizophrenia market. The increasing awareness and approval of late-stage pipeline molecules will drive the market's growth over the coming years, but lack of curative treatment and increasing generic penetration will limit the growth.

This reports provides a data-driven overview of the current and future competitive landscape in schizophrenia therapeutics.

Scope

Components of the report include -

• Disease epidemiology
• Marketed drugs assessment
• Pipeline drugs assessment
• Clinical trials assessment
• Commercial assessment
• Social media overview
• Digital marketing overview

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global schizophrenia market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1.Table of Contents

• 1.1 Preface
• 1.2 Abbreviations
• 1.3 Related Reports
• 1.4 Upcoming Related Reports

2 Executive Summary

• 2.1 Key Findings
• 2.2 Key Events

3 Introduction

• 3.1 Report Scope
• 3.2 Disease Overview Epidemiology Overview
• 3.3 Epidemiology

4 Marketed Drugs Assessment

• 4.1 Marketed Drugs Overview
• 4.2 Marketed Drug Profiles

5 Pipeline Assessment

• 5.1 Pipeline Overview
• 5.2 Pipeline Breakdown by Region
• 5.3 Pipeline Breakdown by Molecule Type and Target
• 5.4 Drug Review Designations
• 5.5 Phase Transition Success Rates
• 5.6 Likelihood of Approval

6 Clinical Trial Assessment

• 6.1 Clinical Trials Overview by Phase
• 6.2 Overview by Region
• 6.4 Therapy Area Perspective
• 6.4 Leading Sponsors
• 6.5 Enrollment Analytics
• 6.6 Feasibility Analysis

7 Commercial Assessment

• 7.1 Upcoming Market Catalysts

8 Social Media and Digital Marketing

• 8.1 Key Twitter Chatter
• 8.2 Top Branded Websites
• 8.3 Trust Flow and Citation Flow

9 Appendix

• 9.1 Methodology
• 9.2 About the Authors
• 9.3 About GlobalData
• 9.4 Contact Us
• 9.5 Disclaimer